HC Wainwright Reaffirms Buy Rating for Nektar Therapeutics (NASDAQ:NKTR)

HC Wainwright restated their buy rating on shares of Nektar Therapeutics (NASDAQ:NKTRFree Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $6.50 price target on the biopharmaceutical company’s stock.

Several other research firms also recently weighed in on NKTR. Piper Sandler began coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They issued an “overweight” rating and a $7.00 target price for the company. BTIG Research reissued a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Finally, B. Riley began coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $4.00 target price for the company. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Nektar Therapeutics has an average rating of “Moderate Buy” and an average price target of $4.08.

View Our Latest Stock Report on NKTR

Nektar Therapeutics Stock Performance

NKTR opened at $0.96 on Monday. The company has a 50-day moving average of $1.07 and a 200-day moving average of $1.21. The company has a market capitalization of $177.32 million, a P/E ratio of -1.14 and a beta of 0.59. Nektar Therapeutics has a 1-year low of $0.48 and a 1-year high of $1.93.

Insider Activity at Nektar Therapeutics

In other Nektar Therapeutics news, insider Jonathan Zalevsky sold 51,115 shares of the business’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10. Following the completion of the transaction, the insider now directly owns 326,904 shares of the company’s stock, valued at $307,289.76. The trade was a 13.52 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mark Andrew Wilson sold 33,402 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the transaction, the insider now directly owns 351,892 shares of the company’s stock, valued at $316,702.80. The trade was a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 155,575 shares of company stock valued at $149,878 in the last quarter. Insiders own 3.71% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NKTR. Victory Capital Management Inc. acquired a new position in Nektar Therapeutics during the 2nd quarter valued at about $29,000. Valence8 US LP acquired a new position in Nektar Therapeutics during the 3rd quarter valued at about $34,000. Intech Investment Management LLC acquired a new position in Nektar Therapeutics during the 3rd quarter valued at about $41,000. XTX Topco Ltd acquired a new stake in shares of Nektar Therapeutics in the 3rd quarter worth approximately $46,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of Nektar Therapeutics in the 3rd quarter worth approximately $61,000. 75.88% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics Company Profile

(Get Free Report)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

See Also

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.